Session of 2018

SENATE BILL No. 438

By Committee on Ways and Means

3-7

 AN ACT concerning health and healthcare; relating to the Kansas medical assistance program; removing prior authorization requirements for medicaid recipients receiving treatment from certain providers; amending K.S.A. 2017 Supp. 39-7,121b and repealing the existing section.

6 7

Be it enacted by the Legislature of the State of Kansas:

8 Section 1. K.S.A. 2017 Supp. 39-7,121b is hereby amended to read as 9 follows: 39-7,121b. (a) No requirements for prior authorization or other 10 restrictions on medications used to treat mental illnesses-may *shall* be 11 imposed on medicaid recipients, except on medications subject to 12 guidelines developed by the medicaid drug utilization review board 13 according to subsection (b). None of the following shall be construed as 14 restrictions under this subsection:

15 (1) Any alert to a pharmacist that does not deny the claim and can be 16 overridden by the pharmacist;

- (2) prescriber education activities; or
- 17 18

(3) the consolidation of dosing regimens to equivalent doses.

19 (b) The mental health medication advisory committee shall provide 20 recommendations to the medicaid drug utilization review board for the 21 purpose of developing guidelines. The medicaid drug utilization review 22 board may accept the recommendations of the mental health medication 23 advisory committee in whole and such recommendations shall take effect 24 immediately upon such approval. The medicaid drug utilization review 25 board may reject the recommendations of the mental health medication 26 advisory committee in whole and such recommendations shall be referred 27 back to the mental health medication advisory committee for further 28 consideration. No medication guidelines related to mental health 29 medications shall be adopted by the medicaid drug utilization review 30 board without recommendations made by the mental health medication 31 advisory committee.

(c) For the medications used to treat mental illness that are available for use on July 1, 2015, the medicaid drug utilization review board shall review all such medications prior to July 1, 2016. For medications used to treat mental illness that do not exist on July 1, 2015, but are laterdeveloped or believed to be effective in the treatment of mental illness, the 1 medicaid drug utilization board shall review all such medications within 2 six months of presentation to the medicaid drug utilization review board.

3 (d) The mental health medication advisory committee is hereby 4 established.

5 (1) The mental health medication advisory committee shall be 6 appointed by the secretary of health and environment and consist of nine 7 members;, including: The secretary of health and environment, or the 8 secretary's designee, who shall be the chair of the committee; two persons 9 licensed to practice medicine and surgery with board certification in psychiatry nominated by the Kansas psychiatric society, one of whom 10 specializes in geriatric mental health; two persons licensed to practice 11 medicine and surgery with board certification in psychiatry nominated by 12 13 the association of community mental health centers of Kansas, one of whom specializes in pediatric mental health; two pharmacists nominated 14 15 by the Kansas pharmacists association; one person licensed to practice 16 medicine and surgery nominated by the Kansas medical society; and one 17 advanced practice registered nurse engaged in a role of mental health 18 nominated by the Kansas state nurses association. All nominating bodies 19 shall provide two nominees for each position for which they provide 20 nominations, with the secretary selecting the appointee from the provided 21 nominees.

(2) The mental health medication advisory committee shall meet
 upon the request of the chair of the mental health medication advisory
 committee, but shall meet at least one time each *calendar* quarter.

(3) Members of the mental health medication advisory committee are entitled to compensation and expenses as provided in K.S.A. 75-3223, and amendments thereto. Members of the committee attending committee meetings shall be paid mileage and all other applicable expenses, provided such expenses are consistent with policies established by the secretary of health and environment.

(e) Notwithstanding the provisions of subsection (a), no requirements
 for prior authorization or other restrictions on medications used to treat
 mental illnesses shall be imposed on medicaid recipients who are
 receiving services from or are being treated by:

(1) Any private treatment facility, as defined in K.S.A. 59-29b46, and
 amendments thereto;

any public treatment facility, as defined in K.S.A. 59-29b46, and
 amendments thereto;

39 (3) any community mental health center organized pursuant to K.S.A.
40 19-4001 through 19-4015, and amendments thereto, and licensed pursuant
41 to K.S.A. 2017 Supp. 39-2001 et seq., and amendments thereto;

42 (4) any mental health clinic organized pursuant to K.S.A. 65-211 43 through 65-215, and amendments thereto, and licensed pursuant to K.S.A. 6 7

2017 Supp. 39-2001 et seq., and amendments thereto; 1

(5) any psychiatric hospital, as defined in K.S.A. 2017 Supp. 39-2 2002, and amendments thereto; 3

4 (6) any psychiatric residential treatment facility, as defined in K.S.A.

- 2017 Supp. 39-2002, and amendments thereto; or 5

 - (7) Osawatomie state hospital or Larned state hospital.
 Sec. 2. K.S.A. 2017 Supp. 39-7,121b is hereby repealed.
- Sec. 3. This act shall take effect and be in force from and after its 8 9 publication in the statute book.